Pinion Investment Advisors LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 125.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,302 shares of the company's stock after purchasing an additional 39,615 shares during the quarter. Pinion Investment Advisors LLC's holdings in Kenvue were worth $1,710,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently bought and sold shares of KVUE. LaFleur & Godfrey LLC grew its holdings in Kenvue by 29.8% during the fourth quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock valued at $1,736,000 after purchasing an additional 18,650 shares during the last quarter. Apollon Wealth Management LLC grew its stake in Kenvue by 16.5% in the 4th quarter. Apollon Wealth Management LLC now owns 11,701 shares of the company's stock valued at $250,000 after buying an additional 1,653 shares during the last quarter. Savant Capital LLC raised its holdings in Kenvue by 5.2% in the 4th quarter. Savant Capital LLC now owns 16,241 shares of the company's stock worth $347,000 after acquiring an additional 798 shares during the period. Focus Financial Network Inc. lifted its position in Kenvue by 10.5% during the 4th quarter. Focus Financial Network Inc. now owns 11,529 shares of the company's stock worth $246,000 after acquiring an additional 1,095 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Kenvue during the fourth quarter valued at about $128,000. 97.64% of the stock is currently owned by institutional investors.
Kenvue Price Performance
NYSE KVUE traded up $0.08 on Monday, reaching $21.53. The company's stock had a trading volume of 4,219,287 shares, compared to its average volume of 16,441,620. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $41.30 billion, a PE ratio of 40.63, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98. The business has a 50-day moving average price of $23.03 and a 200 day moving average price of $22.48.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company's revenue was down 3.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.81%. Kenvue's payout ratio is presently 149.09%.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. UBS Group lifted their price target on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Evercore ISI started coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Barclays upped their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Finally, Piper Sandler increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $25.33.
Read Our Latest Report on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
